Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Upcoming)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Perivascular macrophages mediate the neurovascular and cognitive dysfunction associated with hypertension
Giuseppe Faraco, … , Joseph Anrather, Costantino Iadecola
Giuseppe Faraco, … , Joseph Anrather, Costantino Iadecola
Published November 14, 2016
Citation Information: J Clin Invest. 2016;126(12):4674-4689. https://doi.org/10.1172/JCI86950.
View: Text | PDF
Research Article Neuroscience Vascular biology

Perivascular macrophages mediate the neurovascular and cognitive dysfunction associated with hypertension

  • Text
  • PDF
Abstract

Hypertension is a leading risk factor for dementia, but the mechanisms underlying its damaging effects on the brain are poorly understood. Due to a lack of energy reserves, the brain relies on continuous delivery of blood flow to its active regions in accordance with their dynamic metabolic needs. Hypertension disrupts these vital regulatory mechanisms, leading to the neuronal dysfunction and damage underlying cognitive impairment. Elucidating the cellular bases of these impairments is essential for developing new therapies. Perivascular macrophages (PVMs) represent a distinct population of resident brain macrophages that serves key homeostatic roles but also has the potential to generate large amounts of reactive oxygen species (ROS). Here, we report that PVMs are critical in driving the alterations in neurovascular regulation and attendant cognitive impairment in mouse models of hypertension. This effect was mediated by an increase in blood-brain barrier permeability that allowed angiotensin II to enter the perivascular space and activate angiotensin type 1 receptors in PVMs, leading to production of ROS through the superoxide-producing enzyme NOX2. These findings unveil a pathogenic role of PVMs in the neurovascular and cognitive dysfunction associated with hypertension and identify these cells as a putative therapeutic target for diseases associated with cerebrovascular oxidative stress.

Authors

Giuseppe Faraco, Yukio Sugiyama, Diane Lane, Lidia Garcia-Bonilla, Haejoo Chang, Monica M. Santisteban, Gianfranco Racchumi, Michelle Murphy, Nico Van Rooijen, Joseph Anrather, Costantino Iadecola

×

Figure 2

Slow pressor ANGII disrupts the BBB, leading to ANGII entry into the perivascular space and PVMs.

Options: View larger image (or click on image) Download as PowerPoint
Slow pressor ANGII disrupts the BBB, leading to ANGII entry into the per...
(A) Slow pressor ANGII gradually increases systolic blood pressure measured by tail-cuff plethysmography. *P < 0.05 vs. vehicle (Veh); n = 12–17 (2-way ANOVA and Bonferroni’s test). (B) ANGII plasma levels are increased after 2 weeks of ANGII administration. *P < 0.05 vs. Veh; n = 8–9 (Student’s t test). (C) Slow pressor hypertension but not acute i.v. ANGII administration increases BBB permeability to FITC-dextran (MW 3 kDa). *P < 0.05 vs. Veh; n = 5–7 (Student’s t test). (D) Confocal microscopy showing immunofluorescence labeling of biotinylated ANGII around cerebral blood vessels and in association with PVMs in mice treated with ANGII for 14 days but not in saline-treated mice (scale bar: 25 μm). (E) Orthogonal views (XY, XZ, YZ) illustrating colocalization of biotin-ANGII (green) and CD206 (blue). (F) Biotin-ANGII is associated with PVMs in mice treated with ANGII for 14 days but not in saline-treated mice or in mice acutely infused with ANGII. *P < 0.05 vs. Veh and acute ANGII; n = 3–4 per group; 86 ± 9 PVMs per animal (1-way ANOVA and Tukey’s test). (G) Electron micrographs of cortical arterioles showing immunoperoxidase labeling of biotinylated ANGII tracking along tight junctions (arrows) and reaching perivascular space (arrowheads) in mice treated with ANGII for 14 days (right) but not in saline-treated mice (left). Scale bar: 100 nm. PVM, perivascular macrophage; EC, endothelial cell; VSMC, vascular smooth muscle cells; BM, basement membrane.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts